Zepbound (Tirzepatide): Dosage, Results, and How It Compares to Wegovy
Zepbound is the weight-loss brand name for tirzepatide, the GLP-1/GIP dual agonist from Eli Lilly that produced the strongest Phase 3 weight loss numbers seen from any approved drug before retatrutide entered Phase 2. In the SURMOUNT-1 trial, people on the highest dose lost an average of 20.9% of body weight over 72 weeks. That is not a selective data point. It was the mean, in a well-powered placebo-controlled trial, at a population level.
This guide covers how tirzepatide works, what the trial data actually shows across all dose arms, the approved escalation protocol, the side effect profile, and how Zepbound stacks up against Wegovy (semaglutide 2.4 mg) on every dimension that matters to researchers and clinicians tracking the GLP-1 space.
What Is Zepbound and How Is It Different from Mounjaro?
Both Zepbound and Mounjaro contain tirzepatide, the same peptide molecule at the same doses. The difference is the FDA-approved indication and the branding. Mounjaro was approved in May 2022 for type 2 diabetes management. Zepbound was approved in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea.
Same drug. Different approval pathway. Eli Lilly markets them under separate names partly for commercial reasons and partly because the payer landscape for obesity and diabetes drugs differs substantially. In practice, some physicians prescribe Mounjaro off-label for weight loss, and some prescribe Zepbound for patients with both diabetes and obesity, though the latter has coverage nuances that vary by insurer.
How Tirzepatide Works: Dual Receptor Mechanism
Tirzepatide is a dual agonist. It activates two incretin receptors that are normally stimulated by gut hormones released after eating.
- GLP-1 receptor (glucagon-like peptide-1): slows gastric emptying, suppresses appetite signals in the hypothalamus, and stimulates glucose-dependent insulin secretion. This is the same receptor targeted by semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda).
- GIP receptor (glucose-dependent insulinotropic polypeptide): amplifies the insulin response to meals, improves insulin sensitivity in adipose and skeletal muscle tissue, and appears to modulate the nausea that GLP-1 agonism alone typically produces.
The GIP component is what separates tirzepatide mechanistically from all GLP-1 monotherapy drugs. GIP receptors are expressed on fat cells, and GIP signaling appears to redirect fatty acids away from storage under certain metabolic conditions. More practically, clinical data suggests the GIP agonism contributes meaningfully to the weight loss advantage tirzepatide shows over semaglutide, not just through additive appetite suppression but through distinct metabolic pathways.
For the mechanism comparison to retatrutide, which adds glucagon receptor agonism to the GLP-1/GIP combination, see the tirzepatide vs retatrutide guide. For the full GLP-1 drug comparison including semaglutide and cagrilintide, see the weight loss peptides overview.
SURMOUNT Trial Results: What the Data Shows
The SURMOUNT program is the Phase 3 trial package that supported Zepbound's FDA approval. SURMOUNT-1, the pivotal trial, enrolled 2,539 adults with obesity or overweight without type 2 diabetes. Participants were randomized to 5 mg, 10 mg, or 15 mg tirzepatide weekly or placebo, all alongside lifestyle intervention, for 72 weeks.
| Dose | Average weight loss at 72 wks | Participants losing >20% | Participants losing >25% |
|---|---|---|---|
| 5 mg/week | 15.0% | 30% | 16% |
| 10 mg/week | 19.5% | 50% | 29% |
| 15 mg/week | 20.9% | 57% | 39% |
| Placebo | 2.7% | 3% | 1% |
SURMOUNT-2 enrolled 938 adults with type 2 diabetes alongside obesity, a population with typically harder-to-achieve weight loss. Even in that group, the 15 mg arm lost an average of 15.7% body weight versus 3.3% placebo at 72 weeks, showing that the effect holds across metabolic subpopulations.
SURMOUNT-3 looked at response after an intensive lifestyle intervention lead-in phase, finding that the 15 mg group lost an additional 18.4% on top of the weight already lost in the lead-in. SURMOUNT-4 studied weight regain after stopping the drug, confirming that the majority of people regain weight within a year of discontinuation without maintenance dosing.
Zepbound Dosage Protocol
The approved escalation schedule is conservative, designed to minimize GI side effects during dose increases. The standard protocol:
| Weeks | Dose | Purpose |
|---|---|---|
| Weeks 1-4 | 2.5 mg once weekly | Initiation / GI tolerance building |
| Weeks 5-8 | 5 mg once weekly | First therapeutic dose |
| Weeks 9-12 | 7.5 mg once weekly | Escalation (if tolerated) |
| Weeks 13-16 | 10 mg once weekly | Escalation (if tolerated) |
| Weeks 17-20 | 12.5 mg once weekly | Escalation (if tolerated) |
| Week 21+ | 15 mg once weekly | Maximum approved maintenance dose |
Escalation is not mandatory. If a patient experiences significant side effects at a given dose, clinicians typically hold at that dose for an additional four weeks before attempting to increase again. Some people find adequate efficacy at 10 mg and never need to escalate to 15 mg. The dose-response curve for weight loss is not linear. The jump from 10 mg to 15 mg adds about 1.4 percentage points of mean weight loss in trials, which is meaningful at population level but may not justify tolerability trade-offs in individual cases.
Injections are subcutaneous, typically in the abdomen, upper arm, or thigh. The same injection site rotation principles that apply to other subcutaneous peptides apply here. For the detailed injection technique, see the injection guide.
Zepbound vs Wegovy: Direct Comparison
No head-to-head randomized trial between Zepbound and Wegovy has been published with primary endpoints, though the SURMOUNT-CVOT and SELECT trials provide some cross-trial context. The comparison below is based on published Phase 3 data from separate trials with different populations and follow-up durations, so interpret it accordingly.
| Feature | Zepbound (tirzepatide 15 mg) | Wegovy (semaglutide 2.4 mg) |
|---|---|---|
| Mechanism | GLP-1 + GIP dual agonist | GLP-1 agonist only |
| Average weight loss (trial) | 20.9% at 72 weeks (SURMOUNT-1) | ~15.2% at 68 weeks (STEP 1) |
| % losing >20% body weight | 57% | ~30% |
| Injection frequency | Once weekly | Once weekly |
| Escalation period | 20 weeks to max dose | 16 weeks to max dose |
| Nausea incidence | ~30% (may be lower than semaglutide due to GIP) | ~44% (STEP trials) |
| Cardiovascular outcome data | SURMOUNT-CVOT: 17% reduction in MACE (2025) | SELECT: 20% reduction in MACE (2023) |
| FDA approval (obesity) | November 2023 | June 2021 |
The consistent finding across indirect comparisons is that tirzepatide produces greater average weight loss than semaglutide at approved doses. The mechanistic explanation is that GIP co-agonism adds weight loss beyond what GLP-1 agonism achieves alone. Nausea, the most burdensome side effect of GLP-1 drugs, also appears somewhat lower with tirzepatide, possibly because GIP signaling has a buffering effect on GLP-1-induced gastric symptoms.
For a deeper comparison including liraglutide and the emerging cagrilintide-semaglutide combination, see the semaglutide vs tirzepatide guide.
Side Effects: What to Expect
The side effect profile of tirzepatide closely mirrors other GLP-1 receptor agonists, with some differences that may favor tolerability.
Common (affecting more than 10% of users in trials)
- Nausea: Most common during dose escalation. Reported by approximately 30% of participants at therapeutic doses. Usually manageable with smaller meal sizes and slower eating pace.
- Diarrhea: Reported by approximately 23% of trial participants. Often coincides with nausea during escalation phases.
- Vomiting: Reported by approximately 13%. More likely if nausea is not managed early.
- Constipation: Paradoxically common despite the drug's tendency to cause diarrhea in some people. Gastric slowing is the likely mechanism. Magnesium glycinate and increased fiber intake help most people.
- Injection site reactions: Redness, swelling, or mild pain at injection sites. Rotating sites reduces frequency.
Less Common but Notable
- Fatigue: Especially in the first few weeks. Often improves as the body adapts to reduced caloric intake and the drug's metabolic effects stabilize.
- Hair thinning: Reported anecdotally across GLP-1 users and likely related to rapid weight loss and caloric restriction rather than the drug itself. Adequate protein intake (1.2-1.6 g per kg of body weight) significantly reduces incidence.
- Muscle loss: Rapid weight loss on any agent risks lean mass reduction. Resistance training and high protein intake are the mitigation. See the recovery peptide guide for compounds that may support tissue preservation during caloric deficits.
Serious (Rare, Requires Monitoring)
- Pancreatitis: Rare but documented across GLP-1 drug class. Abdominal pain radiating to the back warrants immediate evaluation.
- Gallbladder disease: Rapid weight loss increases gallstone risk regardless of the agent. Ursodiol prophylaxis is sometimes prescribed for higher-risk patients.
- Thyroid C-cell tumors: Observed in rodent studies at high doses. The clinical relevance in humans is uncertain, but the prescribing label contraindicates use in patients with a personal or family history of medullary thyroid cancer or MEN2.
For the complete side effect breakdown including a week-by-week experience account, see the tirzepatide side effects guide.
Where Zepbound Fits in the GLP-1 Landscape
As of mid-2026, the GLP-1/incretin drug class has four meaningfully differentiated options at or near approval for weight management:
- Wegovy (semaglutide 2.4 mg): GLP-1 only, 15% average weight loss, the most established long-term safety record in obesity.
- Zepbound (tirzepatide 15 mg): GLP-1 + GIP, 21% average weight loss, approved 2023, now the best-established dual agonist.
- Retatrutide (LY3437943): GLP-1 + GIP + glucagon triple agonist, 24% average weight loss in Phase 2, regulatory submission in progress. See the retatrutide guide for full data.
- CagriSema (cagrilintide + semaglutide): GLP-1 + amylin combination, approximately 22-25% weight loss in Phase 3 REDEFINE trials, regulatory filing expected in late 2026. See the cagrilintide guide for trial details.
For researchers or clinicians tracking the field, Zepbound represents the current approved ceiling in single-molecule weight loss efficacy. The next tier (retatrutide, CagriSema) has shown stronger Phase 2/3 numbers but lacks Zepbound's approvals, post-marketing safety record, and supply chain stability.
Research-Grade Tirzepatide
The vendors below supply tirzepatide and other GLP-1 analogs for verified research purposes, with third-party purity testing documentation. Peptide Bureau does not sell products directly.
Frequently Asked Questions
What is the difference between Zepbound and Mounjaro?
Zepbound and Mounjaro contain the same active compound, tirzepatide, at the same doses. The difference is the FDA-approved indication. Mounjaro was approved in May 2022 for type 2 diabetes management. Zepbound was approved in November 2023 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
How much weight can you lose on Zepbound?
In SURMOUNT-1, participants on the 15 mg dose lost an average of 20.9% of body weight over 72 weeks compared to 2.7% with placebo. At 10 mg, average weight loss was 19.5%, and at 5 mg it was 15%. Individual results vary substantially based on starting weight, diet quality, activity level, and dose tolerance.
What is the starting dose of Zepbound?
The approved starting dose is 2.5 mg once weekly for the first four weeks, then 5 mg weekly. Further escalation in 2.5 mg increments every four weeks, based on tolerability, up to the maximum 15 mg maintenance dose.
Is Zepbound better than Wegovy?
On average trial-measured weight loss, yes: 20.9% for Zepbound 15 mg at 72 weeks versus roughly 15% for Wegovy 2.4 mg at 68 weeks. No direct head-to-head trial has been published. The difference is mechanistic: Zepbound's GIP co-agonism adds weight loss beyond what GLP-1 agonism alone achieves. Nausea may also be somewhat lower with Zepbound. Both have strong cardiovascular outcome data.
What are the most common Zepbound side effects?
Nausea (approximately 30% of users), diarrhea (23%), vomiting (13%), and constipation (11%) are the most common. These are most pronounced during dose escalation and typically improve at steady-state maintenance doses. Injection site reactions occur in a minority of users. Hair thinning is reported anecdotally and is likely related to rapid caloric restriction rather than the drug itself.
How does tirzepatide work for weight loss?
Tirzepatide activates the GLP-1 receptor and the GIP receptor simultaneously. GLP-1 activation reduces appetite and slows gastric emptying. GIP activation amplifies the insulin response, improves insulin sensitivity in fat and muscle tissue, and may buffer some of the GI side effects that GLP-1 agonism alone produces. The dual mechanism produces more weight loss than GLP-1 monotherapy in head-to-head comparisons within the same drug class.